INSILICO(03696): Completes First-in-Human Dosing in Exploratory Trial of AI-Driven Non-Opioid Pain Relief Drug Candidate ISM9528
Insilico Medicine (03696) announced that, only four months after preclinical candidate (PCC) nomination, it has completed first-in-human dosing of ISM9528, a potentially first-in-class non-opioid pain relief drug candidate discovered in Abu Dhabi.
INSILICO(03696) announced that, just four months after preclinical candidate (PCC) nomination, INSILICO has completed first-in-human dosing of ISM9528, a potential first-in-class non-opioid pain relief drug candidate discovered in Abu Dhabi.
The exploratory trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral ISM9528 in healthy adult volunteers. As the study progresses, INSILICO may submit additional documents to relevant regulatory authorities and, subject to regulatory approval, expand this exploratory trial.
ISM9528 was nominated as a PCC by INSILICO's Abu Dhabi team in July 2026, becoming the company's 31st PCC since 2021 and the second PCC generated from its UAE R&D efforts. In preclinical studies, ISM9528, as a potential oral therapy, demonstrated efficacy superior to standard therapies in validated models of acute postoperative pain and neuropathic pain. In addition, comprehensive in vitro and in vivo safety screening across multiple test panels and animal models demonstrated a favorable safety profile, while rapid systemic absorption and excellent blood-brain barrier permeability support favorable DMPK properties.
Related Articles

YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.
YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.






